Climb Bio, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Aoife Brennan BCh MMSc
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 20 William Street Wellesley Hills MA United States of America 02481
- IPO Date
- Aug 10, 2021
- CIK
- 0001768446
- Website
- climbbio.com
- Similar Companies
- Business
- Climb Bio, Inc. operates as a clinical-stage biotechnology company focused on developing innovative therapies for immune-mediated diseases. The company’s main product candidates include budoprutug, an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells to reduce pathogenic autoantibodies in diseases such as systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy; and CLYM116, a preclinical-stage anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody targeting immunoglobulin A nephropathy (IgAN) and other B-cell mediated diseases. Climb Bio advances these therapies through clinical trials with a focus on providing disease-modifying treatments that address significant unmet medical needs. Founded in 2018 and headquartered in Wellesley Hills, Massachusetts, Climb Bio serves a global market with its pipeline of differentiated monoclonal antibodies for autoimmune-driven inflammatory diseases. The company changed its name from Eliem Therapeutics, Inc. to Climb Bio, Inc. in October 2024 as part of a strategic repositioning toward immune-mediated disease therapeutics. Recent major developments include the acquisition of the ex-China rights to the CLYM116 antibody through a licensing agreement with Beijing Mabworks Biotech, for which Climb Bio paid $9 million upfront in early 2024. CLYM116 is designed with an engineered Fc region to enhance blocking of APRIL signaling, offering a potential best-in-class treatment for IgAN. The company is poised to initiate Phase 1 dosing for CLYM116 by the end of 2025 with initial clinical data expected by mid-2026. Climb Bio also reported strong financial footing with $175.8 million in cash and marketable securities as of September 30, 2025, funding operational plans through 2027. The company has strengthened its leadership team with senior hires in technical operations and workforce strategy to support the clinical development and commercialization readiness of budoprutug and CLYM116. Climb Bio’s product pipeline and strategic moves underscore its focus on advancing transformative immune medicines for patients with limited therapeutic options in autoimmune and B-cell driven diseases worldwide.
Company News
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
Why Is Climb Bio Stock Gaining Friday?
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
Climb Bio, Inc. Announces $110.0 Million Private Placement
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy